Breast Cancer: NSABP B-47 (Iowa Cancer Specialists)

NSABP PROTOCOL B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Objective

The main purpose of this study is to learn if adding a targeted therapy, trastuzumab (Herceptin®), to standard treatment with chemotherapy for early stage, HER2-low breast cancer, will prevent breast cancer from returning.

The findings of a previous study in breast cancer patients revealed that the addition of trastuzumab to combination chemotherapy helped prevent the cancer from coming back and improved the survival in women with HER2-positive breast cancer. (HER2 is a protein that is found on some types of cancer cells. Trastuzumab is a type of protein made in the laboratory that binds to and can kill HER2-positive cancer cells.) There is some indication it might also be effective in patients with HER2-low breast cancer. This study is being done to
learn more about using trastuzumab to treat HER2-low breast cancer.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Sponsor(s)
National Surgical Adjuvant Breast and Bowel Project
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email